Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 17,818 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: dose level 3 Clear all

Conditions: Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions: Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan, CliniMACS CD34 Reagent System, Tacrolimus, Cyclophosphamide, Plerixafor, Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent, Thiotepa, Mycophenolate Mofetil (MMF), Ruxolitinib, Sirolimus; Drug · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Large B-cell Lymphoma, Central Nervous System Lymphoma
Interventions: Golcadomide, Pemetrexed, Rituximab, Dexamethasone; Drug
Lead sponsor: Allison Winter; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Ischemic Stroke
Interventions: alfimeprase; Drug
Lead sponsor: ARCA Biopharma, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Los Angeles, California • Chicago, Illinois • Des Moines, Iowa + 13 more

Conditions: Relapsed Acute Myelogenous Leukemia
Interventions: Clofarabine, Etoposide, Cyclophosphamide, Filgrastim, Cytarabine; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 1 more

Conditions: Safety Issues
Interventions: ICM20, Benznidazole; Drug
Lead sponsor: IC-MedTech Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Glen Burnie, Maryland • Houston, Texas • Falls Church, Virginia

Conditions: Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myelomonocytic Leukemia (M4), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions: idarubicin, cytarabine, bortezomib, etoposide, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 77
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 72 more

Conditions: Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Squamous Cell Carcinoma AJCC v7
Interventions: External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab; Radiation · Other · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Anemia, Kidney Disease
Interventions: AKB-6548, Placebo; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 28
States / cities: Pine Bluff, Arkansas • Covina, California • Los Angeles, California + 25 more

Conditions: Protein Losing Enteropathy
Interventions: ODSH at 0.125 mg/kg/h, ODSH at 0.375 mg/kg/h, ODSH at 0.250 mg/kg/h; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 6 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Healthy
Interventions: PRT064445, Placebo; Biological · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions: MLN4924, Azacitidine; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Stanford, California • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Malignant Glioma
Interventions: Hypofractionated Stereotactic Irradiation, Nivolumab, Bevacizumab, Ipilimumab; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Tampa, Florida • Columbus, Ohio

Conditions: Advanced Solid Tumors
Interventions: Avelumab, M9241, Avelumab (Once weekly), M9241 (MTD), Avelumab (Expansion cohort); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 17
States / cities: San Diego, California • Santa Rosa, California • New Haven, Connecticut + 13 more

Conditions: Non Small Cell Lung Cancer
Interventions: IPI 504 plus Docetaxel, Placebo plus Docetaxel; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 41
States / cities: Chandler, Arizona • Tucson, Arizona • Orange, California + 38 more

Conditions: Rectal Cancer
Interventions: Nitroglycerin 0.2 MG/HR, Nitroglycerin 0.4 MG/HR, Nitroglycerin 0.6 MG/HR; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: Pegcetacoplan; Drug
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Beverly Hills, California • Miami, Florida • Portsmouth, New Hampshire

Conditions: Postoperative Pain, Acute, Skin Cancer
Interventions: Meloxicam 7.5 mg, Meloxicam 15 mg, Acetaminophen 500mg; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 110 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Acute Myeloid Leukemia
Interventions: CPX-351, Midostaurin, Busulfan, Melphalan, Fludarabine, CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor; Drug · Biological
Lead sponsor: Guenther Koehne; Other
Eligibility: 18 Years to 74 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ischemic Stroke
Interventions: TS23; Biological
Lead sponsor: Translational Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Primary Sjögren's Syndrome
Interventions: CFZ533 active - Cohort 1, CFZ533 placebo- Cohort 1, CFZ533 active - Cohort 2, CFZ533 placebo - Cohort 2, CFZ533 active - Cohort 3; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts • Mineola, New York • Duncansville, Pennsylvania

Conditions: Healthy
Interventions: APD791; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: HIV
Interventions: CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702), Aluminum Hydroxide Suspension (Alum), ACU-026-001-1 (labeled as empty LNP); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee

Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma
Interventions: Cyclophosphamide, CAR-T cell, Fludarabine; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Berzosertib, Quality-of-Life Assessment, Therapeutic Conventional Surgery, Whole-Brain Radiotherapy; Drug · Other · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 9
States / cities: Duarte, California • Sacramento, California • Jacksonville, Florida + 5 more

Search by objective public record fields.

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas

Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery

Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote

MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

Meloxicam in Mohs Micrographic Surgery

Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

Strategy for Improving Stroke Treatment Response

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors